Novel inhibitors in development for hepatocellular carcinoma

Bibliography

• Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55(2):74-108
   PubMed Web of Science ®Google Scholar
• Sangiovanni A, Del Ninno E, Fasani P, Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance. Gastroenterology 2004;126(4):1005-14
   PubMed Web of Science ®Google Scholar
• El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999;340(10):745-50
   PubMed Web of Science ®Google Scholar
• Caldwell SH, Crespo DM, Kang HS, Al-Osaimi AM. Obesity and hepatocellular carcinoma. Gastroenterology 2004;127(5 Suppl 1):S97-103
   PubMed Web of Science ®Google Scholar
• El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007;132(7):2557-76
   PubMed Web of Science ®Google Scholar
• Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin liver Dis 1999;19(3):329-38
   PubMed Web of Science ®Google Scholar
• Lo CM, Ngan H, Tso WK, Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002;35(5):1164-71
   PubMed Web of Science ®Google Scholar
• Llovet JM, Real MI, Montana X, Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002;359(9319):1734-9
   PubMed Web of Science ®Google Scholar
• Lopez PM, Villanueva A, Llovet JM. Systematic review: evidence-based management of hepatocellular carcinoma-an updated analysis of randomized controlled trials. Aliment Pharmacol Ther 2006;23(11):1535-47
   PubMed Web of Science ®Google Scholar
• Zhu AX. Systemic therapy of advanced hepatocellular carcinoma: how hopeful should we be? Oncologist 2006;11(7):790-800
   PubMed Web of Science ®Google Scholar
• Worns MA, Weinmann A, Schuchmann M, Galle PR. Systemic therapies in hepatocellular carcinoma. Dig Dis 2009;27(2):175-88
   PubMed Web of Science ®Google Scholar
• Llovet JM, Di Bisceglie AM, Bruix J, Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008;100(10):698-711
   PubMed Web of Science ®Google Scholar
• Farazi PA, DePinho RA. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer 2006;6(9):674-87
   PubMed Web of Science ®Google Scholar
• Villanueva A, Newell P, Chiang DY, Genomics and signaling pathways in hepatocellular carcinoma. Semin Liver Dis 2007;27(1):55-76
   PubMed Web of Science ®Google Scholar
• Llovet JM, Bruix J. Molecular targeted therapies in hepatocellular carcinoma. Hepatology 2008;48(4):1312-27
   PubMed Web of Science ®Google Scholar
• Avila MA, Berasain C, Sangro B, Prieto J. New therapies for hepatocellular carcinoma. Oncogene 2006;25(27):3866-84
   PubMed Web of Science ®Google Scholar
• Spangenberg HC, Thimme R, Blum HE. Targeted therapy for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2009;6(7):423-32
   PubMed Web of Science ®Google Scholar
• Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004;127(5 Suppl 1):S35-50
   PubMed Web of Science ®Google Scholar
• Therasse P, Arbuck SG, Eisenhauer EA, New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92(3):205-16
   PubMed Web of Science ®Google Scholar
• Wilhelm SM, Carter C, Tang L, BAY 43 – 9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64(19):7099-109
   PubMed Web of Science ®Google Scholar
• Liu L, Cao Y, Chen C, Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 2006;66(24):11851-8
   PubMed Web of Science ®Google Scholar
• Abou-Alfa GK, Schwartz L, Ricci S, Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006;24(26):4293-300
   PubMed Web of Science ®Google Scholar
• Llovet JM, Ricci S, Mazzaferro V, Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359(4):378-90
   PubMed Web of Science ®Google Scholar
• Cheng A, Kang Y, Chen Z, Randomized phase III trial of sorafenib vs placebo in Asian patients with advanced hepatocellular carcinoma. J Clin Oncol 2008
   Google Scholar
• Abou-Alfa GK, Huitzil-Melendez FD, O'Reilly EM, Saltz LB. Current management of advanced hepatocellular carcinoma. Gastrointest Cancer Res 2008;2(2):64-70
   PubMedGoogle Scholar
• Yau T, Chan P, Ng KK, Phase II open-label study of single-agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B-endemic Asian population: presence of lung metastasis predicts poor response. Cancer 2009;115(2):428-36
   PubMed Web of Science ®Google Scholar
• Sherman M, Mazzaferro V, Amadori D, Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma and vascular invasion or extrahepatic spread: a subanalysis from the SHARP trial. J Clin Oncol 2008;26(Suppl): abstract 4584
   Google Scholar
• Pinter M, Sieghart W, Graziadei I, Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis. Oncologist 2009;14(1):70-6
   PubMed Web of Science ®Google Scholar
• Worns MA, Weinmann A, Pfingst K, Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis. J Clin Gastroenterol 2009;43(5):489-95
   PubMed Web of Science ®Google Scholar
• Abou-Alfa GK, Amadori D, Santoro A, Is sorafenib (S) safe and effective in patients (pts) with hepatocellular carcinoma (HCC) and Child-Pugh B (CPB) cirrhosis? J Clin Oncol 2008;26(Suppl): abstract 4518
   Google Scholar
• Imamura H, Matsuyama Y, Tanaka E, Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol 2003;38(2):200-7
   PubMed Web of Science ®Google Scholar
• Sergio A, Cristofori C, Cardin R, Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): the role of angiogenesis and invasiveness. Am J Gastroenterol 2008;103(4):914-21
   PubMed Web of Science ®Google Scholar
• Strebel BM, Dufour JF. Combined approach to hepatocellular carcinoma: a new treatment concept for nonresectable disease. Expert Rev Anticancer Ther 2008;8(11):1743-9
   PubMed Web of Science ®Google Scholar
• Hoffmann K, Glimm H, Radeleff B, Prospective, randomized, double-blind, multi-center, Phase III clinical study on transarterial chemoembolization (TACE) combined with Sorafenib versus TACE plus placebo in patients with hepatocellular cancer before liver transplantation - HeiLivCa [ISRCTN24081794]. BMC Cancer 2008;8:349
   PubMed Web of Science ®Google Scholar
• Miura H, Miyazaki T, Kuroda M, Increased expression of vascular endothelial growth factor in human hepatocellular carcinoma. J Hepatol 1997;27(5):854-61
   PubMed Web of Science ®Google Scholar
• Chao Y, Li CP, Chau GY, Prognostic significance of vascular endothelial growth factor, basic fibroblast growth factor, and angiogenin in patients with resectable hepatocellular carcinoma after surgery. Ann Surg Oncol 2003;10(4):355-62
   PubMed Web of Science ®Google Scholar
• Poon RT, Ho JW, Tong CS, Prognostic significance of serum vascular endothelial growth factor and endostatin in patients with hepatocellular carcinoma. Br J Surg 2004;91(10):1354-60
   PubMed Web of Science ®Google Scholar
• Hurwitz H, Fehrenbacher L, Novotny W, Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350(23):2335-42
   PubMed Web of Science ®Google Scholar
• Malka D, Dromain C, Farace F, Bevacizumab in patients (pts) with advanced hepatocellular carcinoma (HCC): preliminary results of a phase II study with circulating endothelial cell (CEC) monitoring. J Clin Oncol 2007;25(Suppl): abstract 4570
   PubMed Web of Science ®Google Scholar
• Siegel AB, Cohen EI, Ocean A, Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol 2008;26(18):2992-8
   PubMed Web of Science ®Google Scholar
• Zhu AX, Blaszkowsky LS, Ryan DP, Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006;24(12):1898-903
   PubMed Web of Science ®Google Scholar
• Sun W, Haller DG, Mykulowycz K, Combination of capecitabine, oxaliplatin with bevacizumab in treatment of advanced hepatocellular carcinoma (HCC): a phase II study. J Clin Oncol 2007;24(Suppl): abstract 4574
   Google Scholar
• Hsu C, Yang T, Hsu C, Phase II study of bevacizumab (A) plus capecitabine (X) in patients (pts) with advanced/metastatic hepatocellular carcinoma (HCC): final report. J Clin Oncol 2008;26(Suppl): abstract 4603
   Google Scholar
• Finn RS, Zhu AX. Targeting angiogenesis in hepatocellular carcinoma: focus on VEGF and bevacizumab. Expert Rev Anticancer Ther 2009;9(4):503-9
   PubMed Web of Science ®Google Scholar
• Thomas MB, Morris JS, Chadha R, Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. J Clin Oncol 2009;27(6):843-50
   PubMed Web of Science ®Google Scholar
• Llovet JM, Bruix J. Testing molecular therapies in hepatocellular carcinoma: the need for randomized Phase II trials. J Clin Oncol 2009;27(6):833-5
   PubMed Web of Science ®Google Scholar
• Ong LC, Song IC, Jin Y, Effective inhibition of xenografts of hepatocellular carcinoma (HepG2) by rapamycin and bevacizumab in an intrahepatic model. Mol Imaging Biol 2009;11(5):334-42
   PubMed Web of Science ®Google Scholar
• Demetri GD, van Oosterom AT, Garrett CR, Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006;368(9544):1329-38
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Tomczak P, Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356(2):115-24
   PubMed Web of Science ®Google Scholar
• Rini BI. Sunitinib. Expert Opin Pharmacother 2007;8(14):2359-69
   PubMed Web of Science ®Google Scholar
• Faivre S, Demetri G, Sargent W, Raymond E. Molecular basis for sunitinib efficacy and future clinical development. Nat Rev Drug Discov 2007;6(9):734-45
   PubMed Web of Science ®Google Scholar
• Zhu AX, Sahani DV, Duda DG, Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol 2009;27(18):3027-35
   PubMed Web of Science ®Google Scholar
• Faivre S, Raymond E, Boucher E, Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study. Lancet Oncol 2009;10(8):794-800
   PubMed Web of Science ®Google Scholar
• Faivre SJ, Bouattour M, Dreyer C, Raymond E. Sunitinib in hepatocellular carcinoma: redefining appropriate dosing, schedule, and activity end points. J Clin Oncol 2009;27(35):e248-50, e251-42
   PubMed Web of Science ®Google Scholar
• Forner A, Llovet JM, Bruix J. Sunitinib and the benefits of a negative study. Lancet Oncol 2009;10(8):743-4
   PubMed Web of Science ®Google Scholar
• Hoda D, Catherine C, Strosberg J, Phase II study of sunitinib malate in adult pts (pts) with metastatic or surgically unresectable hepatocellular carcinoma (HCC) [abstract 267]. Gastrointest Cancers Symp, 25-27 January, 2009, Orlando, Florida, USA
   Google Scholar
• Koeberle D, Montemurro M, Samaras P, Continous sunitinib treatment in patients with unresectable hepatocellular carcinoma (HCC): a multicenter phase II trial (SAKK 77/06 and SASL 23). J Clin Oncol 2009;27(Suppl): abstract 4591
   PubMed Web of Science ®Google Scholar
• Liu Y, Poon RT, Li Q, Both antiangiogenesis- and angiogenesis-independent effects are responsible for hepatocellular carcinoma growth arrest by tyrosine kinase inhibitor PTK787/ZK222584. Cancer Res 2005;65(9):3691-9
   PubMed Web of Science ®Google Scholar
• Koch I, Baron A, Roberts S, Influence of hepatic dysfunction on safety, tolerability, and pharmacokinetics (PK) of PTK787/ZK 222584 in patients (pts) with unresectable hepatocellular carcinoma (HCC). J Clin Oncol 2005;23(Suppl): abstract 4134
   Google Scholar
• Morelli MP, Brown AM, Pitts TM, Targeting vascular endothelial growth factor receptor-1 and -3 with cediranib (AZD2171): effects on migration and invasion of gastrointestinal cancer cell lines. Mol Cancer Ther 2009;8(9):2546-58
   PubMed Web of Science ®Google Scholar
• Alberts SR, Morlan BW, Kim GP, NCCTG phase II trial (NO44J) of AZD2171 for patients with hepatocellular carcinoma (HCC) – interim review of toxicity [abstract 186]. Gastrointest Cancers Sympos, 19-21 January 2007, Orlando, Florida, USA
   Google Scholar
• Kanai F, Yoshida H, Tateishi R, Final result of a Phase I/II trial of the oral anti-angiogenesis inhibitor TSU-68 in patients with advanced hepatocellular carcinoma. J Clin Oncol 2008;26(Suppl): abstract 4589
   Google Scholar
• Huynh H, Ngo VC, Fargnoli J, Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma. Clin Cancer Res. 2008;14(19):6146-53
   PubMed Web of Science ®Google Scholar
• Raoul JL, Finn RS, Kang YK, An open-label Phase II study of first- and second-line treatment with brivanib in patients with hepatocellular carcinoma (HCC). J Clin Oncol 2009;27(Suppl): abstract 4577
   Google Scholar
• Zhou J, Goh BC, Albert DH, Chen CS. ABT-869, a promising multi-targeted tyrosine kinase inhibitor: from bench to bedside. J Hematol Oncol 2009;2:33
   PubMed Web of Science ®Google Scholar
• Toh H, Chen P, Carr BI, A phase II study of ABT-869 in hepatocellular carcinoma (HCC): interim analysis. J Clin Oncol 2009;27(Suppl): abstract 4581
   Google Scholar
• Yau CC, Chen PJ, Curtis CM, A phase I study of pazopanib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2009;27(Suppl): abstract 3561
   Google Scholar
• Mitsuhashi N, Shimizu H, Ohtsuka M, Angiopoietins and Tie-2 expression in angiogenesis and proliferation of human hepatocellular carcinoma. Hepatology 2003;37(5):1105-13
   PubMed Web of Science ®Google Scholar
• Liu CJ, Lee PH, Lin DY, Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: a randomized phase II trial for safety and optimal dosage. J Hepatol 2009;50(5):958-68
   PubMed Web of Science ®Google Scholar
• Santoro A, Citterio G, Rimassa L, Phase II trial of NGF-hTNF, a selective vascular targeting agent (VTA), administered at low dose in pre-treated patients with hepatocellular carcinoma (HCC) [abstract 247]. Gastrointest Cancers Sympos, 15-17 January 2009, San Francisco, California, USA
   Google Scholar
• Hisaka T, Yano H, Haramaki M, Expressions of epidermal growth factor family and its receptor in hepatocellular carcinoma cell lines: relationship to cell proliferation. Int J Oncol 1999;14(3):453-60
   PubMed Web of Science ®Google Scholar
• Fausto N. Growth factors in liver development, regeneration and carcinogenesis. Prog Growth Factor Res 1991;3(3):219-34
   PubMedGoogle Scholar
• Yeh YC, Tsai JF, Chuang LY, Elevation of transforming growth factor alpha and its relationship to the epidermal growth factor and alpha-fetoprotein levels in patients with hepatocellular carcinoma. Cancer Res 1987;47(3):896-901
   PubMed Web of Science ®Google Scholar
• Berasain C, Castillo J, Prieto J, Avila MA. New molecular targets for hepatocellular carcinoma: the ErbB1 signaling system. Liver Int 2007;27(2):174-85
   PubMed Web of Science ®Google Scholar
• Huether A, Hopfner M, Sutter AP, Erlotinib induces cell cycle arrest and apoptosis in hepatocellular cancer cells and enhances chemosensitivity towards cytostatics. J Hepatol 2005;43(4):661-9
   PubMed Web of Science ®Google Scholar
• Huether A, Hopfner M, Baradari V, EGFR blockade by cetuximab alone or as combination therapy for growth control of hepatocellular cancer. Biochem Pharmacol 2005;70(11):1568-78
   PubMed Web of Science ®Google Scholar
• Philip PA, Mahoney MR, Allmer C, Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J Clin Oncol 2005;23(27):6657-63
   PubMed Web of Science ®Google Scholar
• Thomas MB, Chadha R, Glover K, Phase II study of erlotinib in patients with unresectable hepatocellular carcinoma. Cancer 2007;110(5):1059-67
   PubMed Web of Science ®Google Scholar
• Giannelli G, Azzariti A, Sgarra C, ZD6474 inhibits proliferation and invasion of human hepatocellular carcinoma cells. Biochem Pharmacol 2006;71(4):479-85
   PubMed Web of Science ®Google Scholar
• Okamoto K, Neureiter D, Alinger B, The dual EGF/VEGF receptor tyrosine kinase inhibitor AEE788 inhibits growth of human hepatocellular carcinoma xenografts in nude mice. Int J Oncol 2008;33(4):733-42
   PubMed Web of Science ®Google Scholar
• O'Dwyer PJ, Giantonio BJ, Levy DE, Gefitinib in advanced unresectable hepatocellular carcinoma: results from the Eastern Cooperative Oncology Group's Study E1203 J Clin Oncol 2006;24(Suppl): abstract 4143
   Google Scholar
• Ramanathan RK, Belani CP, Singh DA, A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer. Cancer Chemother Pharmacol 2009;64(4):777-83
   PubMed Web of Science ®Google Scholar
• Bekaii-Saab T, Markowitz J, Prescott N, A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas. Clin Cancer Res 2009;15(18):5895-901
   PubMed Web of Science ®Google Scholar
• Gruenwald V, Wilkens L, Gebel M, A phase II open-label study of cetuximab in unresectable hepatocellular carcinoma: final results. J Clin Oncol 2007;25(Suppl): abstract 4598
   Google Scholar
• Zhu AX, Stuart K, Blaszkowsky LS, Phase II study of cetuximab in patients with advanced hepatocellular carcinoma. Cancer 2007;110(3):581-9
   PubMed Web of Science ®Google Scholar
• Asnacios A, Fartoux L, Romano O, Gemcitabine plus oxaliplatin (GEMOX) combined with cetuximab in patients with progressive advanced stage hepatocellular carcinoma: results of a multicenter phase II study. Cancer 2008;112(12):2733-9
   PubMed Web of Science ®Google Scholar
• Louafi S, Boige V, Ducreux M, Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC): results of a phase II study. Cancer 2007;109(7):1384-90
   PubMed Web of Science ®Google Scholar
• Zhu AX. Successful targeted therapies for hepatocellular carcinoma: are we really getting there? Expert Rev Anticancer Ther 2008;8(4):499-505
   PubMed Web of Science ®Google Scholar
• Ito Y, Sasaki Y, Horimoto M, Activation of mitogen-activated protein kinases/extracellular signal-regulated kinases in human hepatocellular carcinoma. Hepatology 1998;27(4):951-8
   PubMed Web of Science ®Google Scholar
• McKillop IH, Schmidt CM, Cahill PA, Sitzmann JV. Altered expression of mitogen-activated protein kinases in a rat model of experimental hepatocellular carcinoma. Hepatology 1997;26(6):1484-91
   PubMed Web of Science ®Google Scholar
• Carloni V, Vizzutti F, Pantaleo P. Farnesyltransferase inhibitor, ABT-100, is a potent liver cancer chemopreventive agent. Clin Cancer Res 2005;11(11):4266-74
   PubMed Web of Science ®Google Scholar
• O'Neil BH, Williams-Goff LW, Kauh J, A phase II study of AZD6244 in advanced or metastatic hepatocellular carcinoma J Clin Oncol 2009;27(Suppl): abstract e15574
   PubMedGoogle Scholar
• Huynh H, Ngo VC, Koong HN, AZD6244 enhances the anti-tumor activity of sorafenib in ectopic and orthotopic models of human hepatocellular carcinoma (HCC). J Hepatol 2009. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Sabatini DM. mTOR and cancer: insights into a complex relationship. Nat Rev Cancer 2006;6(9):729-34
   PubMed Web of Science ®Google Scholar
• Sahin F, Kannangai R, Adegbola O, mTOR and P70 S6 kinase expression in primary liver neoplasms. Clin Cancer Res 2004;10(24):8421-5
   PubMed Web of Science ®Google Scholar
• Sieghart W, Fuereder T, Schmid K, Mammalian target of rapamycin pathway activity in hepatocellular carcinomas of patients undergoing liver transplantation. Transplantation 2007;83(4):425-32
   PubMed Web of Science ®Google Scholar
• Semela D, Piguet AC, Kolev M, Vascular remodeling and antitumoral effects of mTOR inhibition in a rat model of hepatocellular carcinoma. J Hepatol 2007;46(5):840-8
   PubMed Web of Science ®Google Scholar
• Treiber G. mTOR inhibitors for hepatocellular cancer: a forward-moving target. Expert Rev Anticancer Ther 2009;9(2):247-61
   PubMed Web of Science ®Google Scholar
• Rizell M, Andersson M, Cahlin C, Effects of the mTOR inhibitor sirolimus in patients with hepatocellular and cholangiocellular cancer. Int J Clin Oncol 2008;13(1):66-70
   PubMed Web of Science ®Google Scholar
• Decaens T, Luciani A, Itti E, Pilot study of sirolimus in cirrhotic patients with advanced hepatocellular carcinoma [abstract 244]. Gastrointest Cancers Sympos, 15–17 January 2009, San Francisco, California, USA
   Google Scholar
• Chen L, Shiah HS, Chen CY, Randomized, phase I, and pharmacokinetic (PK) study of RAD001, a mTOR inhibitor, in patients (pts) with advanced hepatocellular carcinoma (HCC). J Clin Oncol 2009;27(Suppl): abstract 4587
   Google Scholar
• Campos LT, Nemunaitis J, Stephenson J, Phase II study of single agent perifosine in patients with hepatocellular carcinoma. J Clin Oncol 2009;27(Suppl): abstract e15505
   PubMed Web of Science ®Google Scholar
• de La Coste A, Romagnolo B, Billuart P, Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas. Proc Natl Acad Sci USA 1998;95(15):8847-51
   PubMed Web of Science ®Google Scholar
• Taniguchi K, Roberts LR, Aderca IN, Mutational spectrum of beta-catenin, AXIN1, and AXIN2 in hepatocellular carcinomas and hepatoblastomas. Oncogene 2002;21(31):4863-71
   PubMed Web of Science ®Google Scholar
• Colnot S, Decaens T, Niwa-Kawakita M, Liver-targeted disruption of Apc in mice activates beta-catenin signaling and leads to hepatocellular carcinomas. Proc Natl Acad Sci USA 2004;101(49):17216-21
   PubMed Web of Science ®Google Scholar
• Wei W, Chua MS, Grepper S, So S. Small molecule antagonists of Tcf4/beta-catenin complex inhibit the growth of HCC cells in vitro and in vivo. Int J Cancer 2009. [Epub ahead of print]
   Web of Science ®Google Scholar
• Breuhahn K, Longerich T, Schirmacher P. Dysregulation of growth factor signaling in human hepatocellular carcinoma. Oncogene 2006;25(27):3787-800
   PubMed Web of Science ®Google Scholar
• Hopfner M, Schuppan D, Scherubl H. Growth factor receptors and related signalling pathways as targets for novel treatment strategies of hepatocellular cancer. World J Gastroenterol 2008;14(1):1-14
   PubMed Web of Science ®Google Scholar
• Desbois-Mouthon C, Baron A, Blivet-Van Eggelpoel MJ, Insulin-like growth factor-1 receptor inhibition induces a resistance mechanism via the epidermal growth factor receptor/HER3/AKT signaling pathway: rational basis for cotargeting insulin-like growth factor-1 receptor and epidermal growth factor receptor in hepatocellular carcinoma. Clin Cancer Res 2009;15(17):5445-56
   PubMed Web of Science ®Google Scholar
• Takami T, Kaposi-Novak P, Uchida K, Loss of hepatocyte growth factor/c-Met signaling pathway accelerates early stages of N-nitrosodiethylamine-induced hepatocarcinogenesis. Cancer Res 2007;67(20):9844-51
   PubMed Web of Science ®Google Scholar
• Eder JP, Vande Woude GF, Boerner SA, LoRusso PM. Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. Clin Cancer Res 2009;15(7):220714
   Web of Science ®Google Scholar
• Mitsiades CS, Mitsiades N, Hideshima T, Proteasome inhibitors as therapeutics. Essays Biochem 2005;41:205-18
   PubMed Web of Science ®Google Scholar
• Hegewisch-Becker S, Sterneck M, Schubert U, Phase I/II trial of bortezomib in patients with unresectable hepatocellular carcinoma (HCC) J Clin Oncol 2004;22(Suppl): abstract 4089
   PubMed Web of Science ®Google Scholar
• Chen KF, Yu HC, Liu TH, Synergistic interactions between sorafenib and bortezomib in hepatocellular carcinoma involve PP2A-dependent Akt inactivation. J Hepatol 2009. [Epub ahead of print]
   Web of Science ®Google Scholar
• Singh DA, Taber D, Ansari R, A phase II trial of the epothilone B analog BMS-247550 in patients (pts) with hepatobiliary cancer (HBC): an updated analysis. J Clin Oncol 2006;24(Suppl): abstract 14050
   Google Scholar
• Vernook AP, Poon R, Kang YK, Evaluation of patupilone as monotherapy in patients with advanced hepatocellular carcinoma (HCC). J Clin Oncol 2007;25(Suppl): abstract 15055
   Google Scholar
• Ozturk M, Arslan-Ergul A, Bagislar S, Senescence and immortality in hepatocellular carcinoma. Cancer lett 2009;286(1):103-13
   PubMed Web of Science ®Google Scholar
• Nava-Parada P, Emens LA. GV-1001, an injectable telomerase peptide vaccine for the treatment of solid cancers. Curr Opin Mol Ther 2007;9(5):490-7
   PubMed Web of Science ®Google Scholar
• Finn RS, Aleshin A, Rivera D, Effect of dasatinib, an orally active small molecule inhibitor of both src and abl kinases, on growth of hepatic progenitor subtype human hepatocellular carcinoma in vitro [abstract 169]. Gastrointest Cancers Sympos, 15-17 January 2009, San Francisco, California, USA
   Google Scholar
• Eckel F, von Delius S, Mayr M, Pharmacokinetic and clinical phase II trial of imatinib in patients with impaired liver function and advanced hepatocellular carcinoma. Oncology 2005;69(5):363-71
   PubMed Web of Science ®Google Scholar
• Osipo C, Miele L. Hedgehog signaling in hepatocellular carcinoma: novel therapeutic strategy targeting hedgehog signaling in HCC. Cancer Biol Ther 2006;5(2):238-9
   PubMed Web of Science ®Google Scholar
• Huang S, He J, Zhang X, Activation of the hedgehog pathway in human hepatocellular carcinomas. Carcinogenesis 2006;27(7):1334-40
   PubMed Web of Science ®Google Scholar
• Abou-Alfa GK, Carvajal RD, Chung KY, A non-randomized phase II study of sequential irinotecan (CPT) and flavopiridol (F) in patients (pts) with advanced hepatocellular carcinoma (HCC) J Clin Oncol 2006;24(Suppl): abstract 4148
   Google Scholar
• Villanueva A, Toffanin S, Llovet JM. Linking molecular classification of hepatocellular carcinoma and personalized medicine: preliminary steps. Curr Opin Oncol 2008;20(4):444-53
   PubMed Web of Science ®Google Scholar
• Hoshida Y, Nijman SM, Kobayashi M, Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res 2009;69(18):7385-92
   PubMed Web of Science ®Google Scholar
• Peck-Radosavljevic M, Greten TF, Lammer J, Consensus on the current use of sorafenib for the treatment of hepatocellular carcinoma. Eur J Gastroenterol Hepatol 2010;22(4):391-8
   Google Scholar
• Paez-Ribes M, Allen E, Hudock J, Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009;15(3):220-31
   PubMed Web of Science ®Google Scholar